Clinical characteristics and treatment outcome of adult acute lymphoblastic leukemia with t(4;11)(q21;q23) using a modified hyper-cvad regimen

Acta Haematologica

Volumn 122, Issue 1, 2009, Pages 23-26

  Li, Yenan ^a   Zou, Dehui ^a   Zhao, Yaozhong ^a   Wang, Jianxiang ^a   Qiu, Lugui ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VINCRISTINE; VINDESINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; CLINICAL ASSESSMENT; DISEASE FREE SURVIVAL; FUSION GENE; HUMAN; MLL AF4 GENE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; EPIRUBICIN; FEMALE; HUMANS; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TREATMENT OUTCOME; VINDESINE;

EID: 68349117181     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000232579     Document Type: Article

References (22)

1. Pui CH, Frankel LS, Carroll AJ, Raimondi SC, Shuster JJ, Head DR, Crist WM, Land VJ, Pullen DJ, Steuber CP, Behm FG, Borowitz MJ: Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with the t(4; 11)(q21;q23): a collaborative study of 40 cases. Blood 1991; 77: 440-447.
2. Janssen JW, Ludwig WD, Borkhardt A, Spadinger U, Rieder H, Fonatsch C, Hossfeld DK, Harbott J, Schulz AS, Repp R, Sykora KW, Hoelzer D, Bartram CR: Pre-pre-B acute lymphoblastic leukemia: high frequency of alternatively spliced ALL1-AF4 transcripts and absence of minimal residual disease during complete remission. Blood 1994; 84: 3835-3842.
3. Ludwig WD, Rieder H, Bartram CR, Heinze B, Schwartz S, Gassmann W, Loffler H, Hossfeld D, Heil G, Handt S, Heyll A, Diedrich H, Fischer K, Weiss A, Volkers B, Aydemir U, Fonatsch C, Gokbuget N, Thiel E, Hoelzer D: Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: results of the German multicenter trials GMALL 03/87 and 04/89. Blood 1998; 92: 1898-1909.
4. Vey N, Thomas X, Picard C, Kovascovicz T, Charin C, Cayuela JM, Dombret H, Dastugue N, Huguet F, Bastard C, Stamatoulas A, Giollant M, Tournilhac O, Macintyre E, Buzyn A, Bories D, Kuentz M, Dreyfus F, Delannoy A, Raynaud S, Gratecos N, Bordessoule D, de Botton S, Preudhomme C, Reman O, Troussard X, Pigneux A, Bilhou C, Vernant JP, Boucheix C, Gabert J: Allogeneic stem cell transplantation improves the outcome of adults with t(1; 19)/E2A-PBX1 and t(4; 11)/MLL-AF4 positive bB-cell acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 study. Leukemia 2006; 20: 2155-2161.
5. Faderl S, Jeha S, Kantarjian HM: The biology and therapy of adult acute lymphoblastic leukemia. Cancer 2003; 98: 1337-1354.
6. Pui CH, Relling MV, Downing JR: Acute lymphoblastic leukemia. N Engl J Med 2004; 350: 1535-1548.
7. Parkin JL, Arthur DC, Abramson CS, Mc- Kenna RW, Kersey JH, Heideman RL, Brunning RD: Acute leukemia associated with the t(4; 11) chromosome rearrangement: ultrastructural and immunologic characteristics. Blood 1982; 60: 1321-1331.
8. Levin MD, Michael PM, Garson OM, Tiedemann K, Firkin FC: Clinicopathological characteristics of acute lymphoblastic leukemia with the 4; 11 chromosome translocation. Pathology 1984; 16: 63-66.
9. Hagemeijer A, van Dongen JJ, Slater RM, van't Veer MB, Behrendt H, Hahlen K, Sizoo W, Abels J: Characterization of the blast cells in acute leukemia with translocation (4; 11): report of eight additional cases and of one case with a variant translocation. Leukemia 1987; 1: 24-31.
10. Secker-Walker LM, Prentice HG, Durrant J, Richards S, Hall E, Harrison G: Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA: MRC Adult Leukaemia Working Party. Br J Haematol 1997; 96: 601-610.
11. Wetzler M, Dodge RK, Mrozek K, Carroll AJ, Tantravahi R, Block AW, Pettenati MJ, Le Beau MM, Frankel SR, Stewart CC, Szatrowski TP, Schiffer CA, Larson RA, Bloomfield CD: Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. Blood 1999; 93: 3983-3993.
12. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings outcome. A Collaborative Study of the Group Français de Cytogénétique Hématologique. Blood 1996; 87: 3135-3142.
13. Pui CH, Gaynon PS, Boyett JM, Chessells JM, Baruchel A, Kamps W, Silverman LB, Biondi A, Harms DO, Vilmer E, Schrappe M, Camitta B: Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 2002; 359: 1909-1915.
14. Murphy SB, Bowman WP, Abromowitch M, Mirro J, Ochs J, Rivera G, Pui CH, Fairclough D, Berard CW: Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine. J Clin Oncol 1986; 4: 1732-1739.
15. Koller CA, Kantarjian HM, Thomas D, O'Brien S, Rios MB, Kornblau S, Murphy S, Keating M: The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia. Leukemia 1997; 11: 2039-2044.
16. Khouri IF, Romaguera J, Kantarjian H, Palmer JL, Pugh WC, Korbling M, Hagemeister F, Samuels B, Rodriguez A, Giralt S, Younes A, Przepiorka D, Claxton D, Cabanillas F, Champlin R: Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998; 16: 3803-3809.
17. Thomas DA, Cortes J, O'Brien S, Pierce S, Faderl S, Albitar M, Hagemeister FB, Cabanillas FF, Murphy S, Keating MJ, Kantarjian H: Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol 1999; 17: 2461-2470.
18. Kantarjian HM, O'Brien S, Smith TL, Cortes J, Giles FJ, Beran M, Pierce S, Huh Y, Andreeff M, Koller C, Ha CS, Keating MJ, Murphy S, Freireich EJ: Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000; 18: 547-561.
19. Cortes J, Thomas D, Rios A, Koller C, O'Brien S, Jeha S, Faderl S, Kantarjian H: Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndromerelated Burkitt lymphoma/leukemia. Cancer 2002; 94: 1492-1499.
20. Thomas DA, O'Brien S, Cortes J, Giles FJ, Faderl S, Verstovsek S, Ferrajoli A, Koller C, Beran M, Pierce S, Ha CS, Cabanillas F, Keating MJ, Kantarjian H: Outcome with the hyper- CVAD regimens in lymphoblastic lymphoma. Blood 2004; 104: 1624-1630.
21. Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S, Bueso-Ramos CE, Pierce S, Shan J, Koller C, Beran M, Keating M, Freireich EJ: Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004; 101: 2788-2801.
22. Biondi A, Cimino G, Pieters R, Pui CH: Biological and therapeutic aspects of infant leukemia. Blood 2000; 96: 24-33.